Intrathecal Pumps Market Overview

The global intrathecal pump market was valued at US$ 296.2 million in 2021. This market is expected to grow at a CAGR of 4.7% between 2023-2032. The industry’s major driver is expected to be the rise in chronic disorders like cancer, chronic pancreatitis, back pain, and other chronic conditions. According to the National Cancer Institute (NCI), there were 16.9 million patients affected by cancer in the U.S. in January 2019.

Global Intrathecal Pumps Market Scope:

Type Analysis

In 2021, the morphine segment was responsible for the highest revenue share at more than 30.6%. Morphine, due to its strong receptor affinity and stability, is the best intrathecal drug administered. It also has a lot of user experience. U.S. FDA approved morphine as a long-term treatment for intrathecal pain. The side effects of long-term intrathecal opioid morphine are much less than those of systemic opioids. This will encourage the segment’s growth. Bupivacaine is forecast to grow at a 6.1% annual growth rate over the forecast period. Bupivacaine is an excellent adjunct medication for intrathecal therapy.

Multiple studies have demonstrated that bupivacaine and intrathecal opioids work together to enhance their effectiveness, contributing significantly to their rising market share. Bupivacaine can be used to help patients reduce their oral opioid intake and minimize dose escalations. Bupivacaine has many advantages that will ensure the growth of this segment. The forecast period will see significant growth in the baclofen segment. Intrathecal Baclofen is effective in the treatment of spasticity and pain. It can also be used to treat multiple types of central pain such as post-stroke and musculoskeletal.

Application Analysis

Based on applications, the industry is further split into spasticity and pain. The largest market share, more than 68.8%, was held by the pain application segment. The rising incidence of acute and chronic illnesses, including cancer that causes chronic pain, and other ailments that cause pain, including failing back syndrome, is one of the primary drivers promoting the expansion of this market. Intrathecal pumps are the best option for those with diseases that cause pain. The prevalence of spasticity will significantly rise between 2023 and 2032.

Many market players have been focusing on spasticity treatment. Medtronic’s Intrathecal Baclofen Therapy(ITB) uses Lioresal Intrathecal (baclofen), to be injected into the fluid surrounding a person’s spinal cord in order to treat severe spasticity. Globally, there are increasing stroke rates. According to a 2019 American College of Cardiology Foundation report, every 40 seconds an American experiences a stroke. Additionally, around 795,000 Americans suffer from new and recurrent strokes each year.

Key Market Segments

Type

• Baclofen

• Clonidine

• Bupivacaine

• Ziconotide

• Morphine

• Others

Application

• Pain

• Spasticity

Market Dynamics

The increasing incidences of cancer will likely lead to strong growth opportunities. Technology advancements in intrathecal pumps will likely boost industry growth. The industry’s adoption rate will rise due to technological advancements such as better delivery mechanisms, improved catheter designs, and safety features.

The COVID-19 epidemic moderately affected the industry’s growth. Pandemic-induced social or healthcare disruptions could pose a significant risk to patients with an intrathecal Pump. Patients may miss refills or replacement appointments. This can lead to withdrawal syndrome, which may hinder the industry’s growth. Baclofen is a potentially life-threatening drug that can cause complications such as death, rhabdomyolysis, seizure, and coma. This poses a problem for the industry. The industry is experiencing a rise in product launches by well-known companies. Amneal Pharmaceuticals launched LYVISPAH (baclofen), a drug that treats spasticity caused by multiple sclerosis.

Manufacturers of intrathecal pumps have also been noted to improve their devices’ battery life. This could help reduce future surgery procedures needed to replace them. Cancer pain is on the rise due to an increased survival rate in oncologic patients. 67% of patients suffering from metastatic cancer experience pain. It is the most common symptom. Pain from chronic cancer can usually be managed using pharmacologic therapies, which include analgesia. The alternative route to analgesic administration via intrathecal drug delivery allows for the reduction of side effects while increasing bioavailability. This helps accelerate the industry’s growth.

Regional Analysis

With a 38.2% market share, North America dominates the intrathecal pump market globally. The Asia Pacific is projected to grow at a 6.8% annual growth rate during the forecast period. A large patient base in the Asia Pacific will likely increase product demand. It is anticipated that intrathecal pumps will be more popular due to an increase in the number of pain management centers in India, China, and Japan. Singapore Pain Care Center, a Southeast Asian pain management center that offers an alternative to open surgery, is one example. The growth of the region was largely due to the rising prevalence of pain-related conditions, increasing R&D spending, and the growing number of pain care centers in the U.S. & Canada. There is a growing number of cancers in the U.S., and this has created a need for more effective and sophisticated intrathecal pumps.

The American Cancer Society predicts that there will be 1.8 million new cancer cases in the US year 2020. The rising prevalence of back issues is another factor contributing to the expansion of intrathecal pumps. Approximately 80% of Americans may have back stiffness at some point in their life, as per the American Chiropractic Association. Europe is anticipated to have strong growth during the study period. Rising healthcare infrastructure spending is anticipated to boost product demand in various pain treatment facilities, which would promote regional market expansion.

Key Regions and Countries covered іn thе rероrt:

• North America

  • US

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Russia

  • Spain

  • Rest of Europe

• APAC

  • China

  • Japan

  • South Korea

  • India

  • Rest of Asia-Pacific

• South America

  • Brazil

  • Argentina

  • Rest of South America

• MEA

  • GCC

  • South Africa

  • Israel

  • Rest of MEA

Market Share Analysis

Strategic growth initiatives are key to gaining a competitive edge. Key companies focus on developing mergers, partnerships, product launches, and other strategic growth strategies. Flowonix Medical has received FDA approval for the Prometra II 40 ml programmable Pump for intrathecal Baclofen. In order to keep their foothold on the global market, industry players have adopted a range of strategies including mergers & acquisitions as well as new product developments, joint ventures, and partnerships. Medtronic, for example, was granted FDA approval in January 2018 for a novel clinician program that can be used with SynchroMedTMII intrathecal drug distribution system.

Key Market Players

These are the major players in global intrathecal pumps markets:

• Medtronic plc

• Medallion Therapeutics

• Codman & Shurtleff

• Arrow International Inc.

• Tricumed GmbH

• Flowonix

• Johnsons and Johnsons Services Inc.

• Teleflex incorporated

• Smith’s Medical

• Other Key Players

For the Intrathecal Pumps Market research study, the following years have been considered to estimate the market size: